Evidence map›Paper›PMID 41279473›Full record

ArticlebioRxiv : the preprint server for biology2025

Integrative analysis of genomic and transcriptomic data informs precancer progression in the pancreas.

Kathleen Noller, Jiaying Lai, Daniel Lesperance, Ricky S Adkins, Ahmed Elhossiny, Paola A Guerrero, Kimal I Rajapakshe, Anirban Maitra, Michelle Giglio, Anup Mahurkar and 7 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kathleen NollerInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
Jiaying LaiDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.
Daniel LesperanceInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
Ricky S AdkinsInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
Ahmed ElhossinyDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
Paola A GuerreroDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
Kimal I RajapaksheDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anirban MaitraDepartments of Pathology and Medicine, New York University Grossman School of Medicine and Perlmutter Cancer Center, New York, NY, USA.
Michelle GiglioInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
Anup MahurkarInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
Owen WhiteInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
Marina Pasca Di MaglianoDepartment of Surgery, The University of Michigan Medical School, Ann Arbor, MI, United States.ORCID 0000-0001-9632-9035
Michael F OchsInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
Luciane T KagoharaDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Laura D WoodDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Rachel KarchinDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.
Elana J FertigInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.

Funding

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Sally Nneoma Adebamowo · 2008 to 2026
$51.0M
Clinical Validation Center for Early Detection of Pancreatic CancerU01CA200468 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANIRBAN MAITRA · 2016 to 2026
$11.0M
Tumor Microenvironment Crosstalk Drives Early Lesions in Pancreatic CancerU54CA274371 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Marina Pasca Di Magliano · 2022 to 2026
$9.5M
Training Grant in Cancer BiologyT32CA154274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Toni M Antalis, CURT I CIVIN · 2011 to 2026
$6.8M
PASSCODE (Pancreatic Adenocarcinoma Stromal Reprograming ConSortium COordination, Data Management and Education)U24CA274274 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI J. Jack LEE, ANIRBAN MAITRA · 2022 to 2026
$4.9M
Interrogation of the Impact of Selection on the Evolution of Human PancreaticCancer Precursor LesionsU01CA271273 · NCI · JOHNS HOPKINS UNIVERSITY · PI Elana Fertig, Rachel Karchin · 2022 to 2026
$2.8M
Illuminating Neurodevelopment through Integrated Analysis and Vizualization of Multi-Omic DataR24MH114815 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI HERTZANO, RONNA, WHITE, OWEN R · 2018 to 2020
$2.3M
The gEAR portal - Advancing Data Sharing, Analysis and Discovery for Hearing and Balance ResearchU01DC019370 · NIDCD · UNIVERSITY OF MARYLAND BALTIMORE · PI MAHURKAR, ANUP · 2023 to 2025
$1.8M
The gEAR portal - Advancing Data Sharing, Analysis and Discovery for Hearing and Balance ResearchR01DC019370 · NIDCD · UNIVERSITY OF MARYLAND BALTIMORE · PI MAHURKAR, ANUP · 2021 to 2022
$1.5M
Single-cell and imaging data integration software to spatially resolve the tumor microenvironmentU01CA253403 · NCI · JOHNS HOPKINS UNIVERSITY · PI FERTIG, ELANA · 2020 to 2022
$1.2M
NCI NIH HHS P30 CA134274NCI NIH HHS T32 CA154274NCI NIH HHS U01 CA200468NCI NIH HHS U01 CA253403NCI NIH HHS U01 CA271273NCI NIH HHS U24 CA274274NCI NIH HHS U54 CA274371NIDCD NIH HHS R01 DC019370NIDCD NIH HHS U01 DC019370NIMH NIH HHS R24 MH114815
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) arises from heterogeneous precursor lesions, including intraductal papillary mucinous neoplasms (IPMNs), but the features distinguishing indolent from progressive lesions remain unclear. We performed an integrative analysis of transcriptomic, genomic, and microenvironmental profiles of IPMNs to define multi-omic phenotypes. Using transfer learning, we projected IPMN-derived transcriptional programs onto spatial transcriptomic datasets from IPMNs and pancreatic intraepithelial neoplasias (PanINs). We identified two major phenotypes: one associated with cancer-associated fibroblasts and epithelial-to-mesenchymal transition, shared across IPMN, PanIN, and PDAC; and a second, glycolysis-enriched phenotype with a unique somatic mutation profile specific to IPMN. Spatial mapping further revealed grade-specific enrichment of transcriptional programs and distinct interactions with stromal and immune subtypes, underscoring the role of the precancer microenvironment in progression. These findings establish multi-omic phenotypes that unify genetic, transcriptional, and microenvironmental heterogeneity, providing a framework for distinguishing progressive from indolent precancers and a web-based public atlas for future exploration of these data and transcriptional phenotypes.

Identifiers

PMID41279473
PMCPMC12637499

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.